Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation

Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation

(2013) Mark H. Eckman   ANNALS OF INTERNAL MEDICINE

Comparative Effectiveness of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in the Management of Patients With Nonvalvular Atrial Fibrillation

(2013) J Pink et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II)

(2012) Jeffrey L. Anderson et al.   CIRCULATION

New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials

(2012) Kate M. O'Dell et al.   CLINICAL THERAPEUTICS

Dabigatran Etexilate

(2012) Kate McKeage   PHARMACOECONOMICS

Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation

(2012) Joyce H. S. You et al.   PLoS One

Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis

(2012) Andrea L. Jorgensen et al.   PLoS One

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing

(2011) J A Johnson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing

(2010) P Lenzini et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age

(2010) A-K Hamberg et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prospective alpha allocation in the clarification of optimal anticoagulation through genetics (COAG) trial

(2010) Jungnam Joo et al.   Clinical Trials

Effect of Home Testing of International Normalized Ratio on Clinical Events

(2010) David B. Matchar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discrete Event Simulation: The Preferred Technique for Health Economic Evaluations?

(2010) Jaime J. Caro et al.   VALUE IN HEALTH

Cost-Effectiveness of Genotype-Guided Warfarin Dosing for Patients With Atrial Fibrillation

(2009) Amanda R. Patrick et al.  

Potential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype-Guided Dosing in Patients Starting Warfarin Therapy

(2009) J H S You et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

A Policy Model to Evaluate the Benefits, Risks and Costs of Warfarin Pharmacogenomic Testing

(2009) Lisa M. Meckley et al.   PHARMACOECONOMICS

Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation

(2009) David H. Salinger et al.   Pharmacogenetics and Genomics

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design

(2009) Rianne MF van Schie et al.   PHARMACOGENOMICS

The largest prospective warfarin-treated cohort supports genetic forecasting

(2008) M. Wadelius et al.   BLOOD

Pharmacology and Management of the Vitamin K Antagonists

(2008) Jack Ansell et al.   CHEST

Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?

(2008) A. M. GALLAGHER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Risk factors for nonadherence to warfarin: results from the IN-RANGE study

(2008) Alec B. Platt et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Warfarin Pharmacogenetics

(2008) Nita A Limdi et al.   PHARMACOTHERAPY